CLDF welcomes the brilliant news that Albireo has received European Marketing authorization for Bylvay ™, the first drug treatment for Progressive Familial Intrahepatic Cholestasis (PFIC).
Bylvay ™ (odevixibat) is the first drug approved for the treatment of all subtypes of PFIC. It is a potent, non-systemic ileal bile acid transport inhibitor (IBATi), which does not require refrigeration and is easily administered as a once-daily capsule or opened and sprinkled onto soft foods.
“Many of our families know only too well the effects which PFIC has on a child’s quality of life and we’re very grateful to those who took part in the trials for this new drug” said CLDF Chief Executive, Alison Taylor. The approval of Bylvay gives parents tremendous hope as the first drug treatment for a condition where up until now, the only option has been surgery”.
Albireo are now working with individual countries to finalise access to Bylvay and we shall update our families as soon as we know more.
The full statement from Albireo is available here: https://ir.albireopharma.com/news-releases/news-release-details/albireo-receives-european-marketing-authorization-bylvaytm
